OncoMatch/Clinical Trials/NCT05245656
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Is NCT05245656 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including RB/RBAC alternating and RB for mantle cell lymphoma.
Treatment: RB/RBAC alternating · RB — This is a phase 2, multicenter, open-label, active-controlled randomized trial to determine efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared with standard RB alone in the first-line treatment of elderly patients with mantle cell lymphoma, who are not eligible for high-dose therapy followed by autologous stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
histologically confirmed CD20+ mantle cell lymphoma
Disease stage
Excluded: Stage ANN ARBOR STAGE 1
Ann Arbor stage 1 disease [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: any treatment for hodgkin lymphoma or non-hodgkin lymphoma
Lab requirements
Blood counts
absolute neutrophil counts (anc) ≥ 1,500/ml, platelet counts ≥ 100,000/ml (any anc and platelet counts are allowed, if they were related to bone marrow involvement)
Kidney function
serum creatinine ≤ 2.0mg/dl or crcl ≥40 ml/min based on the cockcroft-gault method
Liver function
≤2.5 times the upper limit of alt (≤5 times the upper limit of alt if the elevation is attributed by underlying lymphoma) and ≤2 times the upper limit of alt (≤3 times the upper limit of total bilirubin if the elevation is attributed by underlying lymphoma)
Cardiac function
lvef ≥50% by echocardiography or muga
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05245656 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages